MPM Bioimpact LLC
13F holdings for Q2 2026 · BOSTON, MA · filed August 14, 2026
MPM Bioimpact LLC reported $1.6B in 13F securities across 37 holdings for Q2 2026, in a Form 13F filed August 14, 2026. The largest positions were CGEM (10.8%), AKTS (9.5%), LQDA (6.7%). Reported value rose 26.6% from the quarter before. It opened 7 new positions, added to 7, trimmed 22 and sold out of 11.
- 13F value Q2 2026
- $1.6B
- Holdings
- 37
- Change vs prior quarter
- +26.6%
- Rank by 13F value
- #1,855
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics Inc. | $177M | 10.8% | 9,731,341 | +27.2% | Added |
| AKTS Aktis Oncology Inc. | $156M | 9.5% | 4,835,872 | 0% | Unchanged |
| LQDA Liquidia Corporation | $111M | 6.7% | 1,386,174 | -1.4% | Trimmed |
| RVMD Revolution Medicines Inc. | $92.2M | 5.6% | 492,483 | -2.8% | Trimmed |
| CORT Corcept Therapeutics Incorporated | $67.0M | 4.1% | 771,028 | -21.8% | Trimmed |
| EWTX Edgewise Therapeutics Inc. | $65.9M | 4.0% | 1,620,780 | -2.4% | Trimmed |
| TVTX Travere Therapeutics Inc. | $63.8M | 3.9% | 1,122,731 | -0.9% | Trimmed |
| DBVT DBV Technologies S.A. | $60.1M | 3.7% | 3,666,284 | -29.7% | Trimmed |
| TRVI Trevi Therapeutics Inc. | $57.3M | 3.5% | 3,073,577 | -6.8% | Trimmed |
| ALMS Alumis Inc. | $56.8M | 3.5% | 2,019,020 | -15.4% | Trimmed |
| Uniqure NV | $56.5M | 3.4% | 1,225,855 | -10.5% | Trimmed |
| RARE Ultragenyx Pharmaceutical Inc. | $47.4M | 2.9% | 1,418,215 | New | New |
| RLAY Relay Therapeutics Inc. | $45.2M | 2.8% | 2,415,672 | +2.4% | Added |
| ABVX Abivax SA | $44.8M | 2.7% | 336,347 | +213.6% | Added |
| DYN Dyne Therapeutics Inc. | $42.7M | 2.6% | 1,922,093 | +36.5% | Added |
| DNTH Dianthus Therapeutics Inc. | $40.9M | 2.5% | 420,002 | -0.9% | Trimmed |
| BIOA BioAge Labs Inc. | $40.9M | 2.5% | 1,667,661 | New | New |
| Urogen Pharma LTD | $34.3M | 2.1% | 933,415 | -1.1% | Trimmed |
| MLTX MoonLake Immunotherapeutics | $31.3M | 1.9% | 1,606,967 | -11.3% | Trimmed |
| PVLA Palvella Therapeutics Inc. | $31.2M | 1.9% | 204,027 | -1.2% | Trimmed |
| TSHA Taysha Gene Therapies Inc. | $30.6M | 1.9% | 4,500,000 | New | New |
| SNDX Syndax Pharmaceuticals Inc. | $29.2M | 1.8% | 1,333,523 | -0.5% | Trimmed |
| GLUE Monte Rosa Therapeutics Inc. | $28.1M | 1.7% | 1,161,081 | -1.3% | Trimmed |
| Zura Bio LTD | $26.4M | 1.6% | 4,472,843 | New | New |
| NTRA Natera Inc. | $25.1M | 1.5% | 92,638 | -0.5% | Trimmed |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $1.6B in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- RARE Ultragenyx Pharmaceutical Inc. New+$47.4M
- BIOA BioAge Labs Inc. New+$40.9M
- CGEM Cullinan Therapeutics Inc. Added+$37.9M
- TSHA Taysha Gene Therapies Inc. New+$30.6M
- ABVX Abivax SA Added+$30.5M
- Zura Bio LTD New+$26.4M
- ANL Adlai Nortye Group Ltd. New+$22.3M
- ANNX Annexon Inc. New+$20.2M
- DYN Dyne Therapeutics Inc. Added+$11.4M
- TRDA Entrada Therapeutics Inc. New+$9.2M
Biggest sells in Q2 2026
- AGIO Agios Pharmaceuticals Inc. Sold out-$44.2M
- XENE Xenon Pharmaceuticals Inc. Sold out-$34.2M
- EVMN Evommune Inc. Sold out-$33.5M
- CYTK Cytokinetics Incorporated Sold out-$33.0M
- DBVT DBV Technologies S.A. Trimmed-$25.4M
- CRVS Corvus Pharmaceuticals Inc. Sold out-$24.5M
- CORT Corcept Therapeutics Incorporated Trimmed-$18.7M
- CLYM Climb Bio Inc. Sold out-$17.8M
- ARQT Arcutis Biotherapeutics Inc. Sold out-$17.3M
- ZYME Zymeworks Inc. Sold out-$14.2M
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 7 new, 7 added, 22 trimmed, 11 sold out.
Sector mix
- Health Care91.6%
- Not listed with us8.4%
13F value by quarter
More holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| STOK Stoke Therapeutics Inc. | $23.7M | 1.4% | 723,314 | -5.7% | Trimmed |
| ANL Adlai Nortye Group Ltd. | $22.3M | 1.4% | 1,936,291 | New | New |
| BLTE Belite Bio Inc | $21.1M | 1.3% | 137,208 | +55.8% | Added |
| Forte Biosciences Inc | $21.0M | 1.3% | 987,448 | -1.3% | Trimmed |
| ORIC Oric Pharmaceuticals Inc. | $20.4M | 1.2% | 1,882,162 | +4.3% | Added |
| TARS Tarsus Pharmaceuticals Inc. | $20.3M | 1.2% | 322,007 | -2.3% | Trimmed |
| ANNX Annexon Inc. | $20.2M | 1.2% | 3,544,354 | New | New |
| DRUG Bright Minds Biosciences Inc. | $14.2M | 0.9% | 202,114 | -4.7% | Trimmed |
| TRDA Entrada Therapeutics Inc. | $9.2M | 0.6% | 1,253,053 | New | New |
| ACRS Aclaris Therapeutics Inc. | $5.5M | 0.3% | 1,042,467 | +166.0% | Added |
| CNTX Context Therapeutics Inc. | $720K | 0.0% | 1,299,046 | -87.8% | Trimmed |
| HOWL Werewolf Therapeutics Inc. | $29K | 0.0% | 80,142 | -93.4% | Trimmed |
Schedule 13D and 13G filings by MPM Bioimpact LLC
Stakes above 5% of a company, filed within days rather than once a quarter.
- 2026-11-13CRBP SCHEDULE 13G filed by Corbus Pharmaceuticals Holdings Inc.Schedule 13G
- 2026-02-17CLYM SCHEDULE 13G filed by Climb Bio Inc.Schedule 13G
- 2025-02-14CMPX SCHEDULE 13G filed by Compass Therapeutics Inc.Schedule 13G
- 2025-01-08CNTX SCHEDULE 13G filed by Context Therapeutics Inc.Schedule 13G
Questions about MPM Bioimpact LLC
- What does MPM Bioimpact LLC own?
- In its Form 13F for Q2 2026, MPM Bioimpact LLC reported 37 holdings worth $1.6B. The five largest were CGEM, AKTS, LQDA, RVMD, CORT.
- What did MPM Bioimpact LLC buy and sell in Q2 2026?
- MPM Bioimpact LLC opened 7 new positions, added to 7, trimmed 22 and sold out of 11 compared with the quarter before.
- When did MPM Bioimpact LLC file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 14, 2026.
From Form 13F filed by MPM Bioimpact LLC (SEC CIK 0001687078) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds